Defining antibody protection against HIV-1 transmission in Hu-PBL-SCID mice

Seminars in Immunology

Volumn 8, Issue 4, 1996, Pages 263-268

  Koup, Richard A ^a   Safrit, Jeffrey T ^a   Weir, Raymond ^a   Gauduin, Marie Claire ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

HIV 1; Monoclonal antibody; SCID; Transmission

Indexed keywords

HUMAN MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; COMBINED IMMUNODEFICIENCY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PERIPHERAL LYMPHOCYTE; PERITONEAL CAVITY; REVIEW; SCID MOUSE; TARGET CELL; VIRUS TRANSMISSION;

EID: 0030220206     PISSN: 10445323     EISSN: None     Source Type: Journal    
DOI: 10.1006/smim.1996.0033     Document Type: Review

References (52)

1. 1. Custer RP, Bosma GC, Bosma MJ (1985) Severe combined immunodeficiency (SCID) in the mouse. Pathology, reconstitution, neoplasms. Am J Pathol 120:464-477
2. 2. McCune JM, Namikawa R, Kaneshima H, Shultz LD, Lieberman M, Weissman IL (1988) The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function. Science 241:1632-1639
3. 3. Mosier DE, Gulizia RJ, Baird SM, Wilson DB (1988) Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature 335:256-259
4. 4. Duchosal MA, Eming SA, Fischer P, Leturcq D, Barbas CF III, McConahey PJ, Caothien RH, Thornton GB, Dixon FJ, Burton DR (1992) Immunization of hu-PBL-SCID mice and rescue of human monoclonal Fab fragments through combinatorial libraries. Nature 355:258-262
5. 5. Mosier DE (1991) Adoptive transfer of human lymphoid cells to severely immunodeficient mice: models for normal human immune function, autoimmunity, lymphomagenesis, and AIDS. Adv Immunol 50:303-325
6. 6. Mosier DE, Gulizia RJ, Baird SM, Wilson DB, Spector DH, Spector SA (1991) Human immunodeficiency virus infection of human-PBL-SCID mice. Science 251:791-794
7. 7. Mosier DE, Gulizia RJ, MacIsaac PD, Torbett BE, Levy JA (1993) Rapid loss of CD4+ T cells in human-PBL-SCID mice by noncytopathic HIV isolates. Science 260:689-692
8. 8. Safrit JT, Fung MSC, Andrews CA, Braun DG, Sun WNC, Chang TW, Koup RA (1993) Hu-PBL-SCID mice can be protected from HIV-1 infection by passive transfer of monoclonal antibody to the principal neutralizing determinant of the envelope gp 120. AIDS 7:15-21
9. 9. Koup RA, Hesselton RM, Safrit JT, Somasundaran M, Sullivan JL (1994) Quantitative assessment of human immunodeficiency virus type 1 replication in human xenografts of acutely-infected Hu-PBL-SCID mice. AIDS Res Human Retrovir 10:279-284
10. 10. Loofbourow JC, Cabasso VJ, Roby RE, Anuskiewicz W (1971) Rabies immune globulin (human). Clinical trials and dose determination. JAMA 217:1825-1831
11. 11. Groothuis JR, Levin MJ, Rodriguez W, Hall CB, Long CE, Kim HW, Lauer BA, Hemming VG, Group TRS (1991) Use of intravenous gamma globulin to passively immunize high-risk children against respiratory syncytial virus: safety and pharmacokinetics. Antimicrob Agents Chemother 35:1469-1473
12. 12. Condie RM, Hall BL, Howard RJ, Fryd D, Simmons RL, Najarian JS (1979) Treatment of life-threatening infections in renal transplant recipients with high-dose intravenous human IgG. Transplant Proc 11:66-68
13. 13. Iwarson S, Ahlmën J, Eriksson E, Hermodsson S, Kjellman H, Ljunggren C, Selander D (1977) Hepatitis B immune globulin in prevention of hepatitis B among hospital staff members. J Infect Dis 135:473-477
14. 14. Seeff LB, Zimmerman HJ, Wright EC, Finkelstein JD, Garcia PP, Greenlee HB, Dietz AA, Leevy CM, Tamburro CH, Schiff ER, Schimmel EM, Zemel R, Zimmon DS, McCollum RW (1977) A randomized, double blind controlled trial of the efficacy of immune serum globulin for the prevention of post-transfusion hepatitis. A Veterans Administration cooperative study. Gastroenterology 72:111-121
15. 15. Mofenson LM, Burns DN (1991) Passive immunization to prevent mother-infant transmission of human immunodeficiency virus: current issues and future directions. Pediatr Infect Dis J 10:456-462
16. 16. Zolla-Pazner S, Gorny MK (1992) Passive immunization for the prevention and treatment of HIV infection. AIDS 6:1235-1247
17. 17. Matthews JH, Roehrig JT (1984) Elicidation of the topography and determination of the protective epitopes of the E glycoprotein of Saint Louis encephalitis virus by passive transfer with monoclonal antibodies. J Immunol 132:1533-1537
18. 18. Kaufman BM, Summers PL, Dubois DR, Eckels KH (1987) Monoclonal antibodies against dengue 2 virus E-glycoprotein protect mice against lethal dengue infection. Am J Trop Med Hyg 36:427-434
19. 19. Dix RD, Pereira L, Baringer JR (1981) Use of a monoclonal antibody directed against herpes simplex virus glycoproteins to protect mice against acute virus-induced neurological disease. Infect Immun 34:192-199
20. 20. Brandriss MW, Schlesinger JJ, Walsh EE, Briselli M (1986) Lethal 17D yellow fever encephalitis in mice. I. Passive protection by monoclonal antibodies to the envelope proteins of 17D yellow fever and dengue 2 viruses. J Gen Virol 67:229-234
21. 21. Kohl S, Strynadka NCJ, Hodges RS, Pereira L (1990) Analysis of the role of antibody-dependent cellular cytotoxic antibody activity in murine neonatal herpes simplex virus infection with antibodies to synthetic peptides of glycoprotein D and monoclonal antibodies to glycoprotein B. J Clin Invest 86:273-278
22. 22. Renegar KB, Small PA (1991) Passive transfer of local immunity to influenza virus infection by IgA antibody. J Immunol 146:1972-1978
23. 23. Byrne JA, Oldstone MBA (1984) Biology of cloned cytotoxic T lymphocytes specific for lymphocytic choriomeningitis virus: clearance of virus in vivo. J Virol 51:682-687
24. 24. Lukacher AE, Braciale VL, Braciale TJ (1984) In vivo effector function of influenza virus-specific cytotoxic T lymphocyte clones is highly specific. J Exp Med 160:814-820
25. 25. Plata F, Langlade-Demoyen P, Abastado JP, Berbar T, Kourilsky P (1987) Retrovirus antigens recognized by cytolytic T lymphocytes activate tumor rejection in vivo. Cell 48:231-240
26. 26. Reddehasse MJ, Mutter W, Munch K, Buring H-J, Kosinski UH (1987) CDS+ T lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity. J Virol 61:3102-3107
27. 27. Gauduin M-C, Safrit JT, Weir R, Fung MSC, Koup RA (1995) Pre-and post-exposure protection against human immunodeficiency virus type 1 infection mediated by a monoclonal antibody. J Infect Dis 171:1203-1209
28. 28. van Kuyk R, Torbett BE, Gulizia RJ, Leath S, Mosier DE, Koenig S (1994) Cloned human CDS+ cytotoxic T lymphocytes protect human peripheral blood leukocyte-severe combined immunodeficient mice from HIV-1 infection by an HLA-unrestricted mechanism. J Immunol 153:2826-2833
29. 29. Spira AI, Marx PA, Patterson BK, Mahoney J, Koup RA, Wolinsky SM, Ho DD (1996) Cellular targets of infection and route of viral dissemination following an intravaginal inoculation of SIV into rhesus macaques. J Exp Med 183:215-225
30. 30. Fung MSC, Sun C, Sun N-C, Chang NT, Chang TW (1987) Monoclonal antibodies that neutralize HIV-1 virions and inhibit syncytium formation by infected cells. Bio/Technology 5:940-946
31. 31. Liou RS, Rosen EM, Fung MS, Sun WN, Sun C, Gordon W, Chang NT, Chang TW (1989) A chimeric mouse-human antibody that retains specificity for HIV gp 120 and mediates the lysis of HIV-infected cells. J Immunol 143:3967-3975
32. 32. Gunthard HF, Gowland P, Schupbach J, Fung MSC, Boni J, Liou R-S, Chang NT, Grob P, Graepel P, Braun DG, Luthy R (1994) A phase I/ IIA clinical study with a monoclonal chimeric mouse/ human antibody to the V3 loop of HIV-1 gp 120. J Infect Dis 170:1384-1393
33. 33. Andrus L (1993) Passive immunization against HIV-1 infection using HIV immune globulins (HIVIG). (Girard M, Valette L, eds) pp 251-257. Foundation Merieux, Paris
34. 34. Scott CFJ, Silver S, Profy AT, Putney SD, Langlois A, Weinhold K, Robinson JE (1990) Human monoclonal antibody that recognizes the V3 region of human immunodeficiency virus gp 120 and neutralizes the human T-lymphotropic virus type IIIMN strain. Proc Natl Acad Sci USA 87:8597-8601
35. 35. Gorny MK, Conley AJ, Karwowska S, Buchbinder A, Xu JY Emini EA, Koenig S, Zolla-Pazner S (1992) Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody. J Virol 66:7538-7542
36. 36. Gorny MK, Xu JY, Karwowska S, Buchbinder A, Zolla-Pazner S (1993) Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp 120. J Immunol 150:635-643
37. 37. Tilley SA, Honnen WJ, Racho ME, Chou TC, Pinter A (1992) Synergistic neutralization of HIV-1 by monoclonal antibodies against the V3 loop and CD4-binding site of gp 120. AIDS Res Human Retrovir 8:461-467
38. 38. Laal S, Burda S, Gorny MK, Karwowska S, Buchbinder A, Zolla-Pazner S (1994) Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies. J Virol 68:4001-4008
39. 39. Ashkenazi A, Smith DH, Marsters SA, Riddle L, Gregory TJ, Ho DD, Capon DJ (1991) Resistance of primary isolates of human immunodeficiency virus type 1 to soluble CD4 is independent of CD4-rgp 120 binding affinity. Proc Natl Acad Sci USA 88:7056-7060
40. 40. Daar ES, Ho DD (1991) Relative resistance of primary HIV-1 isolates to neutralization by soluble CD4. AM J Med 90:22S-26S
41. 41. Moore JP, Cao Y, Qing L, Sattentau QJ, Pyati J, Koduri R, Robinson J, Barbas CF III, Burton DR, Ho DD (1995) Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp 120. J Virol 69:101-109
42. 42. Moore JP, McKeating JA, Huang YX, Ashkenazi A, Ho DD (1992) Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp 120 retention from sCD4-sensitive isolates. J Virol 66:235-243
43. 43. Burton DR, Pyati J, Koduri R, Sharp SJ, Thornton GB, Parren PWHI, Sawyer LSW, Hendry RM, Dunlop N, Nara PL, Lamachia M, Garratty E, Stiehm ER, Bryson YJ, Cao Y, Moore JP, Ho DD, Barbas CFI (1994) Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266:1024-1027
44. 44. Allaway GP, David-Bruno KL, Beaudry GA, Garcia EB, Wong EL, Ryder AM, Hasel KW, Gauduin M-C, Koup RA, McDougal JS, Maddon PJ (1995) Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. AIDS Res Human Retrovir 11:533-539
45. 45. Moore JP, Trkola A, Korber B, Bouts LJ, Kessler II JA, McCutchan FE, Mascola J, Ho DD, Robinson J, Conley AJ (1995) A human monoclonal antibody to a complex epitope in the V3 region of human immunodeficiency virus type 1 has broad reactivity within and outside clade B. J Virol 69:122-130
46. 46. Trkola A, Pomales AP, Yuan H, Korber B, Maddon PJ, Allaway GP, Katinger H, Barbas CF III, Burton DR, Ho DD, Moore JP (1995) Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J Virol 69:6609-6617
47. 47. Parren PW, Ditzel HJ, Gulizia RJ, Binley JM, Barbas CF III, Burton DR, Mosier DE (1995) Protection against HIV-1 infection in hu-PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp 120 CD4-binding site. AIDS 9:F1-6
48. 48. Gauduin M-C, Allaway GP, Maddon PJ, Barbas CF III, Burton DR, Koup RA (1996) Effective ex vivo neutralization of human immunodeficiency virus type 1 in plasma by recombinant immunoglobulin molecules. J Virol 70:2586-2592
49. 49. Moore JP, Nara PL (1991) The role of the V3 loop of gp 120 in HIV infection. AIDS 5:S21-S33
50. 50. Moore JP, Ho DD (1993) Antibodies to discontinuous or con formation ally sensitive epitopes on the gp 120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans. J Virol 67:863-875
51. 51. Cao Y, Qing L, Zhang LQ, Safrit JT, Ho DD (1994) Virological and immunological characterization of long-term survivors of HIV-1 infection. N Engl J Med 332:201-208
52. 52. Layne SP, Merges MJ, Spouge JL, Dembo M, Nara PL (1991) Blocking of human immunodeficiency virus infection depends on cell density and viral stock age. J Virol 65:3293-3300